stockrow
Friday 6 November 2026
Export LGVN’s income statement to Excel — free account
Longeveron Inc.
LGVN Healthcare Biotechnology
Longeveron Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 49.9% from fiscal 2024.
- Revenue
- −9.18%
- EPS
- +42.4%
- Free cash flow
- −49.1%
Quarter to June 2026, against a year earlier
1.79
0.08
+4.68%
Follow LGVN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | 2 | 6 | 6 | 1 | 1 | 1 | 2 | 1 | 1 | (7.9%) | 2 | 2 | 3 | +34.2% | |
| Gross margin, % | — | — | 31.88 | 31.10 | 32.44 | 45.18 | 40.67 | 31.17 | 78.76 | 66.97 | 69.76 | +35.1 pt | ||||||
| EBT | — | — | (6) | (3) | (4) | (17) | (19) | (21) | (16) | (23) | (23) | +20.0% | ||||||
| EBT margin, % | — | — | (296.83) | (52.49) | (66.10) | (1,305.13) | (1,541.33) | (3,020.17) | (667.77) | (1,893.58) | (1,977.59) | (1,596.7) pt | ||||||
| Net income | — | 0 | (6) | (3) | (4) | (17) | (19) | (21) | (16) | (23) | (23) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.11 | 0.30 | 35.14 | 6.90 | 5.83 | 3.26 | 2.54 | 0.68 | 0.38 | +29.5% | |||||
| Earnings | — | — | (0.33) | (0.15) | (23.20) | (90.00) | (90.00) | (102.00) | (26.20) | (12.90) | (10.18) | +68.8% | ||||||
| Cash flow | — | — | (0.27) | (0.13) | (14.76) | (50.93) | (66.61) | (87.43) | (14.74) | (10.61) | (6.49) | +68.9% | ||||||
| Capex | — | — | 0.00 | (0.01) | (1.63) | (6.47) | (4.08) | (3.19) | (1.05) | (0.34) | (0.15) | n/m | ||||||
| Free cash flow | — | — | (0.27) | (0.13) | (16.39) | (57.40) | (70.70) | (90.62) | (15.79) | (10.95) | (6.64) | +69.6% | ||||||
| Book value | — | — | 0.36 | 0.23 | 12.22 | 197.95 | 97.77 | 31.01 | 23.26 | 3.23 | 3.32 | +37.0% | ||||||
| Shares, m | — | — | 19 | 19 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | (28.9%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | 21.09 | 21.09 | 21.09 | 174.86 | 57.83 | 40.46 | 10.84 | 7.42 | 4.73 | 44.3 | ||||||
| P/B | — | — | 60.66 | 60.66 | 60.66 | 6.10 | 3.45 | 4.26 | 1.19 | 1.57 | 0.54 | 24.8 | ||||||
| EV/Sales | — | — | 21.02 | 21.02 | 21.02 | 150.02 | 43.42 | 34.94 | 3.15 | 3.68 | (3.10) | 37.3 | ||||||
| EV/FCF | — | — | (45.07) | (45.07) | (45.07) | (17.95) | (3.58) | (1.26) | (0.51) | (0.23) | 0.18 | (19.8) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (5) | (2) | (2) | (10) | (14) | (19) | (14) | (19) | (20) | +20.1% | |||||
| Capex | — | — | 0 | 0 | 0 | (1) | (1) | (1) | (1) | (1) | 0 | +15.9% | ||||||
| Free cash flow | — | — | (5) | (3) | (3) | (11) | (15) | (20) | (15) | (19) | (21) | +20.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 2 | 0 | (2) | 33 | 15 | 2 | 17 | 1 | 7 | (7.2%) | |||||
| Net debt | — | — | (4) | 2 | 0 | (32) | (18) | (4) | (18) | (4) | (10) | +1.6% | ||||||
| Shareholders’ equity | — | — | 7 | 4 | 2 | 37 | 21 | 7 | 22 | 6 | 10 | (2.6%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (120.45) | (28.05) | (37.54) | (65.55) | (53.68) | (112.49) | (130.85) | (126.77) | (145.64) | (6.3) pt | |||||
| ROIC | — | — | 0.00 | (27.89) | (148.41) | (217.55) | (390.74) | (464.75) | (296.82) | (1,230.29) | (4,549.04) | (1,230.3) pt | ||||||
| ROE | — | — | (112.56) | (52.58) | (116.24) | (86.50) | (65.00) | (163.05) | (172.02) | (164.75) | (203.61) | (52.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 12 | 12 | 22 | 21 | 24 | 26 | 38 | — | +21.2% | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.47 | 0.47 | 0.06 | 0.06 | 0.03 | 0.09 | 0.03 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Longeveron Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| XCUR Exicure, Inc. | $5.8M | — (loss-making) | — (loss-making) | −80.51% (below 0%: shrinking) | n/m | +65.38% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ORGS Orgenesis Inc. | $5.7M | — (loss-making) | 1.0× | +82.42% (above 0%: growing) | n/m | −317.93% (below 0%: shrinking) | 2,780.73% | (6,044.52%) | Compare |
| CRIS Curis, Inc. | $5.7M | — (loss-making) | — (loss-making) | −65.98% (below 0%: shrinking) | n/m | −20.44% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| LGVN Longeveron Inc. | $5.5M | — (loss-making) | — (loss-making) | −9.18% (below 0%: shrinking) | n/m | −49.12% (below 0%: shrinking) | 63.41% | (2,150.17%) | |
| ACXP Acurx Pharmaceuticals, Inc. | $5.3M | — (loss-making) | — | — | n/m | −2.36% (below 0%: shrinking) | — | 0.00% | Compare |
| PCSA Heatwurx Inc. | $5.1M | — (loss-making) | — | −64.29% (below 0%: shrinking) | n/m | +20.29% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SNTI Senti Biosciences, Inc. | $5.1M | — (loss-making) | — (loss-making) | −98.68% (below 0%: shrinking) | n/m | −7.48% (below 0%: shrinking) | 100.00% | (85,229.41%) | Compare |
| PULM Pulmatrix, Inc. | $5.1M | — (loss-making) | — (loss-making) | −99.86% (below 0%: shrinking) | n/m | +41.26% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CNSY Cerenome, Inc. | $5.1M | — (loss-making) | — (loss-making) | −70.43% (below 0%: shrinking) | n/m | −31.46% (below 0%: shrinking) | 100.00% | (2,203.65%) | Compare |
| Median of peers | $5.2M | — | — | −70.43% | — | −4.92% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 20 May 2026
Ownership
Directors and executive officers, together
7.20%
Joshua M. Hare, M.D.
3.80%
The Estate of Donald M. Soffer
2.10%
Lee Cohen Hare
1.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement